Impact of Clinical Pharmacists in Inflammatory Bowel Disease Centers During the COVID-19 Pandemic.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 32694291.
- Also identified by DOI 10.14309/ajg.0000000000000787 and PMC identifier 7396223.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To characterize the clinical pharmacists' impact on caring for patients with inflammatory bowel disease during COVID-19. A clinical pharmacist's encounters between March 17 and April 14, 2020, were audited to determine encounter frequency and indication. The clinical pharmacist addressed COVID-19 and inflammatory bowel disease treatment concerns with 140 patients, conducted 34 medication education and monitoring visits, reviewed 141 patients' charts and helped rescheduled 18 patients who missed their biologic infusion, transitioned 12 patients to home infusions, and assisted 5 patients with medication access. Clinical pharmacists embedded in gastroenterology practices permit for continued optimal patient care during a pandemic.
Medical subject headings
- Betacoronavirus
- Clinical Audit
- Coronavirus Infections
- Inflammatory Bowel Diseases
- Patient Care
- Patient Care Team
- Pharmacists
- Pneumonia, Viral